Akums Drugs and Pharmaceuticals Ltd has reported a 5.9% rise in consolidated revenue to ₹43,590.17 Million for the financial year 2025-26 (FY26). The company’s EBITDA improved 13.3% to ₹5,220.30 Million, while Adjusted Profit After Tax rose 27.3% to ₹2,760 Million. The Integrated Annual Report for FY26 was released on June 18, 2026, detailing the financial performance and operational expansion.

Financial Performance

Consolidated revenue from operations increased to ₹43,590.17 Million in FY26 from ₹41,181.58 Million in FY25, while total income grew 7.6% to ₹44,877.42 Million. EBITDA margins expanded to 12.0% from 11.2%. The company reported a net cash position of ₹16,087 Million as of March 31, 2026.

Segment-Wise Performance

The Contract Development and Manufacturing Organisation (CDMO) segment drove growth, contributing approximately 80% of consolidated revenue with an 8.6% year-on-year increase. Domestic Branded Formulations EBITDA grew 17%, while International Branded Formulations EBITDA surged 32.3%.

Global Expansion and AGM Details

Akums Healthcare (Zambia) Private Limited was incorporated on October 13, 2025, as a 51:49 joint venture with the Zambian government. The $45 Million facility in Lusaka is slated to begin operations in CY 2028, with the government committing to procure USD 25 Million annually for FY27 and FY28. In Europe, the company initiated commercial dispatches to Switzerland and incorporated subsidiaries in the UK and Malta.

The 22nd AGM is scheduled for Friday, July 10, 2026, at 11:00 A.M. (IST) through Video Conferencing (VC) and Other Audio-Visual Means (OAVM). Remote e-voting will be available from Monday, July 6, 2026, at 9:00 A.M. (IST) to Thursday, July 9, 2026, at 5:00 P.M. (IST). Members whose names are recorded in the Register of Members or in the Register of Beneficial Owners as on the cut-off date of July 3, 2026, are entitled to vote.

Akums Drugs and Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. The report details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBC) principles, covering environmental, social, and governance aspects of its operations. The disclosures have been assured by BDO India Services Private Limited, with reasonable assurance provided for core indicators and limited assurance for essential and leadership indicators.

Environmental Performance

The company reported a total energy consumption of 10,96,245.52 GJ for FY 2025-26, compared to 10,68,818.03 GJ in the previous year. Energy intensity per ₹ crore of turnover improved to 251.49 GJ from 259.54 GJ. Renewable energy sources contributed 3,36,446.52 GJ to the total consumption. Total Scope 1 and Scope 2 greenhouse gas emissions were 1,38,181.40 metric tonnes of CO2 equivalent, with an emission intensity of 31.65 metric tonnes per ₹ crore of revenue.

Water withdrawal totalled 11,34,998.46 kilolitres, primarily from groundwater sources. Water discharge was reported at 1,04,240.89 kilolitres. The company operates Zero Liquid Discharge (ZLD) facilities at three manufacturing sites. Waste generation totalled 9,204.67 metric tonnes, with 6,591.61 metric tonnes recovered through recycling, reusing, or other recovery operations.

Social and Governance Metrics

The company employed 6,455 permanent employees and 11,555 workers as of the end of FY 2025-26. The workforce included 31 differently abled employees and 18 differently abled workers. The Board of Directors comprised 8 members, with female representation at 12.50%. The company reported 4 sexual harassment complaints during the year, all of which were resolved.

Financial and Regulatory Disclosures

The report disclosed that the company paid penalties totaling ₹8,34,999 during the year for various regulatory non-compliances, including issues related to misbranding and stock exchange regulations. The company’s turnover stood at ₹1,348.74 crore, and its net worth was ₹2,305.25 crore. Akums Drugs and Pharmaceuticals Limited continues to focus on integrating ESG considerations into its business strategy, with initiatives aimed at improving energy efficiency, water stewardship, and waste management.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE09XN01023/85efcf7226914b05.pdf